Enrollment

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Martedì, Maggio 14, 2024
Patient, Epidemiology, Cell, Survival, University, PLN, Risk, Nature Communications, PKP2, Cardiomyopathy, Research and development, Workforce, Heart failure, Investment, AAV, Clinical trial, Doctor of Philosophy, ARVC, Therapy, Safety, HCM, Chemistry, Biopsy, CMC, HEK, Gene, Enrollment, Cas9, HDAC6, Society, CRISPR, G&A, Administration, Second Half, Antibody, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • “The year is off to a strong start for Tenaya,” said Faraz Ali, Chief Executive Officer of Tenaya.
  • Tenaya anticipates sharing initial safety, biopsy and biomarker data from the first cohort of patients in the MyPEAK-1 trial in the second half of 2024.
  • General & Administrative (G&A) Expenses: Year-over year G&A expenses were relatively flat at $8.7 million for the first quarter of 2024 and $8.1 million for the first quarter of 2023.
  • Non-cash stock-based compensation included in G&A expense was $2.2 million for the first quarter of 2024 compared to $1.9 million for the first quarter of 2023.

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Retrieved on: 
Giovedì, Maggio 9, 2024
FDA, Investment, Risk, Destiny, IND, Autoimmune disease, Enrollment, Death, Hospital, GAAP, NK, GEJ, Multiple myeloma, CRS, HER2, Pharmacokinetics, Graft-versus-host disease, Food, Lupus, Data, ADR, BCL, Histology, Therapy, BCMA, Autoimmunity, Safety, Trastuzumab, Research, TRAC, Incidence, IPSC, Chronic lymphocytic leukemia, Acute leukemia, Investigational New Drug, Cancer, Cell, Cmax, Patient, Gene, Society, B-cell lymphoma, BCM, Cytokine release syndrome, Immune system, SLE, Vaccine

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today reported business highlights and financial results for the first quarter ended March 31, 2024.

Key Points: 
  • The patient was discharged after a three-day hospital stay without any notable adverse events.
  • The Company will conduct a conference call today, Thursday, May 9, 2024 at 5:00 p.m.
  • ET to review financial and operating results for the quarter and full year ended March 31, 2024.
  • The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.fatetherapeutics.com.

Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
Giovedì, Maggio 9, 2024
MIBC, FDA, Cancer, Urology, Fast Track, Necrosis, SPA, Safety, General counsel, Research, Recurrence, Growth, Light, Bladder cancer, Immunogenic cell death, Incidence, Patient, Enrollment, Compass, Macrophage, NMIBC, Neoplasm, Annual general meeting, Damage-associated molecular pattern, ARVO, Pharmaceutical industry

BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights.

Key Points: 
  • Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024
    BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights.
  • “Throughout the first quarter of 2024, the Company made significant progress across our ocular and urologic oncology therapeutic area programs,” said Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura.
  • As of March 31, 2024, Aura had cash and cash equivalents and marketable securities totaling $202.9 million.
  • General and administrative expenses include $1.4 million and $1.1 million of stock-based compensation for the three months ended March 31, 2024 and 2023, respectively.

89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Giovedì, Maggio 9, 2024
MASH, University, Patient, Cirrhosis, Research and development, Liver disease, EASL, Safety, Hypertriglyceridemia, Administration, Journal of Clinical Pathology, Hepatology, Virginia Commonwealth University, PRIME, European Medicines Agency, Liver, Enrollment, EMA, Fibrosis, Division, SAN, Pharmaceutical industry

SAN FRANCISCO, May 09, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the first quarter ended March 31, 2024.

Key Points: 
  • SAN FRANCISCO, May 09, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the first quarter ended March 31, 2024.
  • These key clinical developments, coupled with our agreement for commercial supply, are designed to strategically enhance our readiness for potential commercialization."
  • ENLIGHTEN-Cirrhosis, the second trial in the program, is planned to evaluate patients with compensated cirrhosis and is expected to initiate in the second quarter of 2024.
  • As of March 31, 2024, 89bio had cash, cash equivalents and marketable securities of approximately $562.3 million.

Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Martedì, Maggio 7, 2024
American Academy, Research and development, IGNITE, Publication, Research, TREM2, Microglia, Administration, Patient, Enrollment, Interim, Clinical trial, Completeness, Pharmaceutical industry

WATERTOWN, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent progress.

Key Points: 
  • In addition, two posters highlighting the ILLUMINATE Natural History Study of ALSP and the mechanism of action for iluzanebart were also presented.
  • Next data readout from Phase 2 IGNITE clinical trial on track for third quarter of 2024: The Company is on track to report additional data from its Phase 2 clinical trial evaluating iluzanebart in ALSP in the third quarter of 2024.
  • Research and Development (R&D) Expenses: R&D expenses for the first quarter ended March 31, 2024 were $14.3 million, compared to $13.8 million for the same period in 2023.
  • Net Loss: Loss from operations for the first quarter ended March 31, 2024 were $19.9 million, compared to $19.8 million for the same period in 2023.

Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Lunedì, Maggio 6, 2024
AAAAI, Angioedema, Cell, Research, Enrollment, Itch, Atopic dermatitis, Injection, Congress, American Academy, Skin, PN, ILT4, Allergy, KIT, Cold urticaria, Therapy, Omalizumab, Neuropeptide, Patient, UAS7, Survival, PD-1, Rockefeller University, EAACI, Hypersensitivity, Clinical trial, Xeroderma, CSU, G&A, B cell, Prurigo nodularis, Myelocyte, Disease, Inflammation, Eosinophilic esophagitis, Pharmaceutical industry

HAMPTON, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.

Key Points: 
  • Celldex is currently planning two Phase 3 studies of barzolvolimab in CSU, which are expected to initiate this summer.
  • Revenues: Total revenue was $0.2 million in the first quarter of 2024, compared to $1.0 million for the comparable period in 2023.
  • G&A Expenses: General and administrative (G&A) expenses were $9.1 million in the first quarter of 2024, compared to $6.6 million for the comparable period in 2023.
  • Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at March 31, 2024 are sufficient to meet estimated working capital requirements and fund current planned operations through 2027.

PowerSchool Announces First Quarter Financial Results

Retrieved on: 
Martedì, Maggio 7, 2024
Primary, Secondary, Education, Data Management, Technology, Software, Artificial Intelligence, Internet, Momentum, Knowledge, CFO, AI, School, Parent, Learning, Red Hat, Enrollment, GAAP, Schoology, Workload, BETT, International school, K-12, Generative, Visalia Unified School District, Ecosystem, International, ARR, Responsibility, Behavior, Assessment, Microsoft, Student, Treasury, SIS, Synthetic media, BME, UNESCO, Pearson Education, Growth, Toledo City School District

PowerSchool Holdings, Inc. (NYSE: PWSC) ("PowerSchool" or the “Company”), the leading provider of cloud-based software for K-12 education in North America, today announced financial results for its first quarter ended March 31, 2024.

Key Points: 
  • PowerSchool Holdings, Inc. (NYSE: PWSC) ("PowerSchool" or the “Company”), the leading provider of cloud-based software for K-12 education in North America, today announced financial results for its first quarter ended March 31, 2024.
  • “We opened 2024 with a strong first quarter in which we met our revenue guidance and exceeded the high end of our profitability guidance.
  • Finally, PowerSchool joined the UNESCO Global Education Coalition to support the digital transformation of education worldwide.
  • Commenting on the Company’s results, Eric Shander, PowerSchool President and CFO, added, “We demonstrated continued operational excellence and execution in line with our strategy during the first quarter.

Washtenaw Community College, Central State University sign HBCU transfer partnership; HBCU Day hosts 400+ high school students

Retrieved on: 
Venerdì, Maggio 3, 2024
Education, Central State, Community college, WCC, School, Ypsilanti Community Schools, Dream, George Taylor Field, Humanities, Partnership, Social, Engineering, Vocational education, Mathematics, Science, Access, Enrollment, Central State University, Wilberforce University, Student, HBCU, Marching band, Tutoring

WCC President Dr. Rose B. Bellanca welcomed Central State University guests and community leaders at the signing ceremony.

Key Points: 
  • WCC President Dr. Rose B. Bellanca welcomed Central State University guests and community leaders at the signing ceremony.
  • Dr. Arletha McSwain, Vice Provost of Access & Enrollment Management representing Central State University’s Interim President, Dr. Alex Johnson, signed the partnership agreement.
  • Located in Wilberforce, Ohio, Central State boasts a storied heritage with its roots beginning at Wilberforce University, the oldest private HBCU in the nation.
  • Today’s HBCU Day will culminate in a Central State University Marching Band performance and a “Divine Nine Fraternity & Sorority Stroll Off” in the Community Park on WCC’s campus.

Benevis Spotlights the Importance of Dental Coverage for Underserved Populations During Medicaid Awareness Month

Retrieved on: 
Martedì, Aprile 16, 2024
Public, Dental care, Dentistry, Map, Health, Children's Health Insurance Program, Insurance, Patient, Enrollment, CHIP, Child, Dentist, COVID-19, Health insurance

Yet, over the past year, the unwinding of the Medicaid continuous enrollment provision left many without coverage, exasperating the dental coverage divide.

Key Points: 
  • Yet, over the past year, the unwinding of the Medicaid continuous enrollment provision left many without coverage, exasperating the dental coverage divide.
  • "Benevis extends its heartfelt gratitude to all the dental healthcare providers and care teams who tirelessly dedicate their time and effort to treating underserved patient populations.
  • Dentists and hygienists will provide high-quality and compliant dental care from some of its 100 Benevis dental homes to establish equitable access to quality dental care.
  • To learn more about Benevis’ ongoing work to expand the reach of oral care to impact Medicaid and CHIP members, please watch our video .

Santa Clara County School Boards Association Recognizes Morgan Hill Unified School District with Hoffman Award for CARE Program

Retrieved on: 
Lunedì, Aprile 22, 2024
Student Services, Learning, Counselor, School, Partnership, Parent, CARE, McKinney, Texas, Enrollment, Superintendent, Homelessness, Student, Nursing

MORGAN HILL, Calif., April 22, 2024 /PRNewswire/ -- The Santa Clara County School Boards Association (SCCSBA) has awarded the Morgan Hill Unified School District the prestigious Glenn Hoffmann Exemplary Program Award in the targeted student populations category.

Key Points: 
  • MORGAN HILL, Calif., April 22, 2024 /PRNewswire/ -- The Santa Clara County School Boards Association (SCCSBA) has awarded the Morgan Hill Unified School District the prestigious Glenn Hoffmann Exemplary Program Award in the targeted student populations category.
  • This accolade recognizes the school district's outstanding commitment to supporting students through the Coordinated Advocacy and Resources for Education (CARE) program.
  • Following a tour of a Central California School District in 2017, the inception of the CARE program started to take shape.
  • The Morgan Hill Unified School District encompasses 296 square miles and serves the ethnically diverse population of Morgan Hill, San Martin and a small portion of south San Jose.